Ken Griffin Ironwood Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.93 - $7.04 $14,541 - $26,048	3,700 Added 97.37%	7,500 $30,000
Q2 2024 Aug 14, 2024	SELL	$5.58 - $8.61 $3.07 Million - $4.74 Million	-550,100 Reduced 99.31%	3,800 $24,000
Q1 2024 May 15, 2024	BUY	$8.32 - $15.45 $3.43 Million - $6.37 Million	412,000 Added 290.35%	553,900 $4.82 Million
Q4 2023 Feb 14, 2024	BUY	$8.79 - $11.51 $1.17 Million - $1.53 Million	132,700 Added 1442.39%	141,900 $1.62 Million
Q3 2023 Nov 14, 2023	BUY	$8.25 - $11.35 $23,925 - $32,915	2,900 Added 46.03%	9,200 $88,000
Q2 2023 Aug 14, 2023	BUY	$10.1 - $11.6 $18,180 - $20,880	1,800 Added 40.0%	6,300 $67,000
Q1 2023 May 15, 2023	SELL	$10.37 - $12.56 $245,768 - $297,672	-23,700 Reduced 84.04%	4,500 $47,000
Q4 2022 Feb 14, 2023	BUY	$9.9 - $12.43 $279,180 - $350,526	28,200 New	28,200 $349,000

237

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $682M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.